Fidelity Investments
CTNM

Fidelity Investments’s Contineum Therapeutics CTNM Stock Holding History

Fidelity Investments’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Buy
1,040,130
+225,259
+28% +$2.95M ﹤0.01% 1930
2026
Q1 		$10.6M Hold
814,871
– – ﹤0.01% 2023
2025
Q4 		$9.31M Hold
814,871
– – ﹤0.01% 2054
2025
Q3 		$9.57M Sell
814,871
-28,279
-3% -$228K ﹤0.01% 2019
2025
Q2 		$3.35M Buy
843,150
+32,833
+4% +$143K ﹤0.01% 2308
2025
Q1 		$5.66M Buy
810,317
+118,436
+17% +$1.08M ﹤0.01% 2103
2024
Q4 		$10.1M Sell
691,881
-5,046
-0.7% -$79.9K ﹤0.01% 1932
2024
Q3 		$13.3M Buy
696,927
+373,327
+115% +$7.16M ﹤0.01% 1836
2024
Q2 		$5.7M Buy
+323,600
New +$5.21M ﹤0.01% 2041

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Fidelity Investments's CTNM Position: Q2 2026 in Review

Fidelity Investments increased its Contineum Therapeutics (CTNM) stake by 28% in Q2 2026, buying an estimated $2.95M and bringing the position to 1,040,130 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #1930.

Fidelity Investments first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Fidelity Investments held 1,040,130 shares of Contineum Therapeutics worth $17M as of Q2 2026.
  • Fidelity Investments bought 225,259 Contineum Therapeutics shares in Q2 2026, an estimated $2.95M.
  • Contineum Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1930 holding.
  • Fidelity Investments first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.